Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934889 · ClinicalTrials.gov registry record · Phase 1
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
A Phase 1 study of Glioblastoma and Gliosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT06934889: Recruiting Phase 1 study of Glioblastoma and Gliosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06934889 is a Phase 1 study of Glioblastoma and Gliosarcoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (45% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06934889, a Phase 1 study of Glioblastoma and Gliosarcoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Primary Outcome
All patients who receive a single dose of investigational drug will be included in the primary endpoint analysis. Will be measured descriptively using CTCAE v5.0
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG ERAS-801
- DRUG ABBV-637
- DRUG ABBV-155
Study Locations (9)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Florida
- University of Miami (Data collection only) - Miami
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT06934889 shows while recruiting
NCT06934889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (45% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT06934889 lists 9 locations in 4 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT06934889 about?
NCT06934889 is a clinical study titled "Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma". The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
What is the current status of trial NCT06934889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-04-07. Estimated completion is 2028-04.
What conditions does trial NCT06934889 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma.
What interventions are being tested in trial NCT06934889?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), ERAS-801 (DRUG), ABBV-637 (DRUG), ABBV-155 (DRUG).
Who is sponsoring clinical trial NCT06934889?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934889 being conducted?
This trial has 9 study locations across Florida, New Jersey, New York, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06934889's enrollment target sits among peer trials
60 75th of 199 higher than 122 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI